Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
ASLAN Pharmaceuticals Initial Public Offering and NASDAQ Listing
Davis Polk advised the joint book-running managers and representatives of the underwriters in the approximately $42.2…
Unity Biotechnology, Inc. $85 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 5…
Ping An Healthcare and Technology Company Limited HK$8.77 Billion ($1.12 Billion) Initial Public Offering
Davis Polk advised the joint global coordinators in the Hong Kong initial public offering of Ping An Healthcare and…
Trident Clinical Services Holdings credit agreements amendment
We advised the agent in connection with an amendment
Davis Polk Advises McKesson on Its Acquisition of Medical Specialties Distributors
Davis Polk is advising McKesson Corporation on its acquisition of Medical Specialties Distributors, LLC from New Mountain…
Davis Polk Advises Notre Dame Intermédica on Its R$2.4 Billion Initial Public Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the initial public offering by Notre Dame…
Aeglea BioTherapeutics $36 Million Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $36 million SEC-registered common stock…
Shire $2.4 billion sale of its Oncology business to Servier
Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has…
Cellectis S.A. Follow-On Offering
Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis…
PTC Therapeutics, Inc. Common Stock Offering
Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC…